{"id":"zubsolv-sublingual-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine is a partial mu-opioid receptor agonist that provides a ceiling effect on respiratory depression, making it safer than full opioid agonists. Naloxone is an opioid antagonist included to deter intravenous misuse. Together, they work to prevent withdrawal symptoms and reduce the reinforcing effects of illicit opioids.","oneSentence":"Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:54.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"}]},"trialDetails":[{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT03033732","phase":"PHASE4","title":"A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse","status":"COMPLETED","sponsor":"Didier Jutras Aswad","startDate":"2017-10-02","conditions":"Opioid Use Disorder","enrollment":272},{"nctId":"NCT03015246","phase":"PHASE1, PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":"Heroin Dependence, Opioid Use Disorder","enrollment":26},{"nctId":"NCT01550341","phase":"NA","title":"HIV, Buprenorphine, and the Criminal Justice System","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-02-23","conditions":"Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction","enrollment":50},{"nctId":"NCT03766893","phase":"EARLY_PHASE1","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"COMPLETED","sponsor":"Lifespan","startDate":"2018-09-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT03420313","phase":"PHASE2","title":"Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2018-03-01","conditions":"Opioid-use Disorder","enrollment":100},{"nctId":"NCT01967641","phase":"PHASE2","title":"Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-11","conditions":"Opioid Dependence","enrollment":51},{"nctId":"NCT02180659","phase":"PHASE3","title":"A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants","status":"COMPLETED","sponsor":"Titan Pharmaceuticals","startDate":"2014-07","conditions":"Opioid Dependence","enrollment":177},{"nctId":"NCT00768482","phase":"PHASE3","title":"A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2008-09","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT01114308","phase":"PHASE3","title":"A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction","status":"COMPLETED","sponsor":"Titan Pharmaceuticals","startDate":"2010-04","conditions":"Opioid Dependency","enrollment":287},{"nctId":"NCT01188421","phase":"PHASE1, PHASE2","title":"Medications Development for Drug Abuse Disorders","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-10","conditions":"Opioid Related Disorders, Opioid Dependence, Opioid Addiction","enrollment":106},{"nctId":"NCT00604188","phase":"PHASE4","title":"A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-22","conditions":"Opiate Dependence, Drug Dependence, Substance Dependence","enrollment":188},{"nctId":"NCT01260675","phase":"","title":"Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone","status":"COMPLETED","sponsor":"NanoSHIFT LLC","startDate":"2010-12","conditions":"Healthy","enrollment":12},{"nctId":"NCT01848054","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-06","conditions":"Opioid-Related Disorders, Opiate Dependence","enrollment":313},{"nctId":"NCT01908842","phase":"PHASE3","title":"Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-08","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":759},{"nctId":"NCT01396005","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Hepatitis C Virus","enrollment":21},{"nctId":"NCT02038790","phase":"PHASE4","title":"Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Dependence","enrollment":33},{"nctId":"NCT00725608","phase":"","title":"Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-05","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":339},{"nctId":"NCT01582347","phase":"PHASE2","title":"Transfer of Subjects From Subutex/Suboxone to RBP-6300","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-03","conditions":"Opioid Related Disorder","enrollment":143},{"nctId":"NCT00000320","phase":"PHASE1, PHASE2","title":"Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1997-10","conditions":"Opioid-Related Disorders","enrollment":120},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT01846455","phase":"PHASE4","title":"Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-09","conditions":"Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma","enrollment":43},{"nctId":"NCT00605033","phase":"PHASE4","title":"A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-03","conditions":"Opiate Dependence, Drug Dependence","enrollment":241},{"nctId":"NCT01903005","phase":"PHASE4","title":"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-07","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":668},{"nctId":"NCT01052662","phase":"PHASE2, PHASE3","title":"Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-10","conditions":"Opioid Dependence","enrollment":87},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01015066","phase":"PHASE4","title":"Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":"Opiate Addiction","enrollment":""},{"nctId":"NCT00955162","phase":"PHASE4","title":"Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (\"RIME\")","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2009-08","conditions":"Opioid Dependency","enrollment":270},{"nctId":"NCT00901875","phase":"PHASE4","title":"Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2009-03","conditions":"Opiate Dependence","enrollment":127},{"nctId":"NCT00723749","phase":"","title":"Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-03","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":384},{"nctId":"NCT01275599","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Telaprevir and Buprenorphine","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-01","conditions":"Hepatitis C, Opioid-Related Disorders","enrollment":16},{"nctId":"NCT00552578","phase":"PHASE4","title":"Buprenorphine as a Treatment in Opiate Dependent Pain Patients","status":"TERMINATED","sponsor":"State University of New York at Buffalo","startDate":"2007-10","conditions":"Opiate Addiction, Refractory Pain","enrollment":12},{"nctId":"NCT00007527","phase":"PHASE4","title":"Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1999-08","conditions":"Opiate Dependence","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["buprenorphine","naloxone"],"phase":"marketed","status":"active","brandName":"Zubsolv sublingual tablets","genericName":"Zubsolv sublingual tablets","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder. Used for Opioid use disorder maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}